Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized comparison of abciximab i.v. versus i.c. in primary PCI patients with STEMI and effects on infarct size and microvascular obstruction

Trial Profile

Randomized comparison of abciximab i.v. versus i.c. in primary PCI patients with STEMI and effects on infarct size and microvascular obstruction

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary) ; Abciximab (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms LIPSIABciximab-STEMI
  • Most Recent Events

    • 17 Nov 2011 Results reporting the endpoint of aborted myocardial infarction published in the International Journal of Cardiology.
    • 01 May 2011 Results published in Clinical Research in Cardiology.
    • 28 Aug 2010 Results from mid-term follow-up at 6 months presented in an abstract at the Annual Congress of the European Society of Cardiology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top